Key result
In patients with active cancer and venous thromboembolism, direct oral anticoagulants led to thrombosis reduction or resolution in 86% of evaluable patients, with major bleeding occurring in 5.4%.
Why the study?
Are direct oral anticoagulants safe and effective for treating venous thromboembolism in patients with active cancer?
Cohort (n=312)
Are direct oral anticoagulants safe and effective for treating venous thromboembolism in patients with active cancer?
In patients with active cancer and VTE, DOACs demonstrated high rates of thrombosis resolution, though clinically relevant bleeding led to discontinuation in 16% of patients.
Supports DOAC evaluation in cancer-associated VTE; leaves open need for RCTs before practice change.
BACKGROUND/AIM: Although direct oral anti - coagulants (DOACs) are as safe and effective as conventional anticoagulants for treating venous thromboembolism (VTE), we have insufficient evidence justifying their use in patients with active cancer. We investigated the safety and effectiveness of DOACs in patients with active cancer. PATIENTS AND METHODS: To investigate the safety and efficacy of DOACs, we retrospectively extracted 312 consecutive patients with active cancer who were prescribed edoxaban, rivaroxaban or apixaban for VTE. RESULTS: The most common primary cancer sites were the lung, stomach, colon/rectum, hematology, ovary, and pancreas. Fifty patients (16%) discontinued DOACs due to clinically relevant bleeding; major bleeding events occurred in 18 patients (5.4%). Thrombosis reduced or resolved in 144 of 167 evaluable patients (86%). In particular, pulmonary embolism was reduced or resolved in 46 of 50 patients (92%). CONCLUSION: Our findings revealed that DOACs for cancer-associated VTE are as safe and effective as conventional anticoagulation therapy.
No takes yet. Share an insight, caveat, or question.
Ogata et al. (2021) conducted a cohort in Venous thromboembolism in patients with active cancer (n=312). Direct oral anticoagulants (edoxaban, rivaroxaban, or apixaban) was evaluated on Thrombosis reduced or resolved. In patients with active cancer and venous thromboembolism, direct oral anticoagulants led to thrombosis reduction or resolution in 86% of evaluable patients, with major bleeding occurring in 5.4%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: